[go: up one dir, main page]

WO1999031260A3 - Sequences regulatrices intervenant dans l'expression du gene specifique du pancreas - Google Patents

Sequences regulatrices intervenant dans l'expression du gene specifique du pancreas Download PDF

Info

Publication number
WO1999031260A3
WO1999031260A3 PCT/EP1998/008215 EP9808215W WO9931260A3 WO 1999031260 A3 WO1999031260 A3 WO 1999031260A3 EP 9808215 W EP9808215 W EP 9808215W WO 9931260 A3 WO9931260 A3 WO 9931260A3
Authority
WO
WIPO (PCT)
Prior art keywords
regulatory sequences
vectors
recombinant dna
dna molecules
pharmaceutical
Prior art date
Application number
PCT/EP1998/008215
Other languages
English (en)
Other versions
WO1999031260A2 (fr
Inventor
Peter Gruss
Birgitta Kammandel
Original Assignee
Max Planck Gesellschaft
Peter Gruss
Birgitta Kammandel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft, Peter Gruss, Birgitta Kammandel filed Critical Max Planck Gesellschaft
Priority to AU20539/99A priority Critical patent/AU2053999A/en
Publication of WO1999031260A2 publication Critical patent/WO1999031260A2/fr
Publication of WO1999031260A3 publication Critical patent/WO1999031260A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne: des séquences régulatrices du promoteur du gène Pax6 ou d'un gène homologue de Pax6, capable d'activer une expression de cellules pancréatiques; des molécules et vecteurs d'ADN de recombinaison comprenant ces séquences régulatrices et des cellules hôtes transformées par ces dernières; des compositions pharmaceutiques et de diagnostic comprenant ces séquences régulatrices, ainsi que les molécules et vecteurs d'ADN de recombinaison; des animaux non humains transgéniques comprenant les molécules ou vecteurs d'ADN de recombinaison précédemment cités intégrés de manière stable dans leur génome. L'invention concerne également l'utilisation des molécules et vecteurs d'ADN de recombinaison précédemment cités pour la préparation de compositions pharmaceutiques destinées au traitement, à la prévention et/ou au retardement d'une maladie liée au pancréas chez un sujet. En outre, l'invention concerne l'utilisation des séquences régulatrices et des molécules et vecteurs d'ADN de recombinaison de l'invention pour préparer des compositions pharmaceutiques destinées à activer une maladie du pancréas chez un animal non humain; ainsi qu'une méthode d'identification d'agonistes/activateurs ou d'agonistes/inhibiteurs de gènes ou de produits géniques intervenant dans les affections du pancréas grâce aux séquences régulatrices précédemment citées, aux molécules d'ADN de recombinaison, vecteurs, cellules et animaux transgéniques non humains. L'invention concerne enfin des composés pouvant être identifiés grâce à cette méthode, des anticorps contre ces composés et des compositions pharmaceutiques et de diagnostic comprenant ces agonistes/activateurs, antagonistes/inhibiteurs et/ou anticorps.
PCT/EP1998/008215 1997-12-15 1998-12-15 Sequences regulatrices intervenant dans l'expression du gene specifique du pancreas WO1999031260A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU20539/99A AU2053999A (en) 1997-12-15 1998-12-15 Regulatory sequences involved in pancreas-specific gene expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97122103.1 1997-12-15
EP97122103 1997-12-15

Publications (2)

Publication Number Publication Date
WO1999031260A2 WO1999031260A2 (fr) 1999-06-24
WO1999031260A3 true WO1999031260A3 (fr) 1999-08-12

Family

ID=8227804

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/008215 WO1999031260A2 (fr) 1997-12-15 1998-12-15 Sequences regulatrices intervenant dans l'expression du gene specifique du pancreas

Country Status (2)

Country Link
AU (1) AU2053999A (fr)
WO (1) WO1999031260A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028184A (en) * 1996-12-31 2000-02-22 Max-Plank-Gesellschaft Zur Forderung Der Wissenschaften E.V. Pax6 and Pax4 nucleic acid mixtures
US6337392B1 (en) 1998-05-07 2002-01-08 The Rockefeller University Lens transcriptional control elements and methods of use thereof
AU3977799A (en) * 1998-05-07 1999-11-23 New York University Lens transcriptional control elements and methods of use thereof
CA2482907A1 (fr) * 2002-04-16 2003-10-30 Origene Technologies, Inc. Genes et batteries de genes specifiques de tissus
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
CN111202847B (zh) * 2020-02-08 2021-11-30 北京大学第三医院（北京大学第三临床医学院） Pax6基因或其表达产物在制备抑制纤维化的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5416017A (en) * 1990-05-18 1995-05-16 The Scripps Research Institute Cholera toxin gene regulated by tissue-specific promoters

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5416017A (en) * 1990-05-18 1995-05-16 The Scripps Research Institute Cholera toxin gene regulated by tissue-specific promoters

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002104751, Database accession no. Z95332 *
KAMMANDEL B. ET AL.: "Distinct cis-essential modules direct the time-space pattern of the Pax6 gene activity", DEVELOPMENTAL BIOLOGY, vol. 205, no. 1, 1 January 1999 (1999-01-01), pages 79 - 97, XP002105021 *
MILES C. ET AL.: "Complete sequencing of the Fugu WAGR region from WT1 to PAX6: dramatic compaction and conservation of synteny with human chromosome 11p13", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 95, October 1998 (1998-10-01), pages 13068 - 13072, XP002104750 *
PLAZA S. ET AL.: "Quail PAX-6 (PAX-QNR) encodes a transcription factor able to bind and trans-activate its own promoter", CELL GROWTH & DIFFERENTIATION, vol. 4, December 1993 (1993-12-01), pages 1041 - 1050, XP002104749 *
ST-ONGE L. ET AL.: "Pax6 is required for differentiation of glucacon-producing alpha-cells in mouse pancreas", NATURE, vol. 387, 22 May 1997 (1997-05-22), pages 406 - 409, XP002067724 *
TURQUE N. ET AL.: "Pax-QNR/Pax-6, a paired box- and homeobox-containing gene expressed in neurons, is also expressed in pancreatic endocrine cells", MOLECULAR ENDOCRINOLOGY, vol. 8, no. 7, 1 July 1994 (1994-07-01), pages 929 - 938, XP002067722 *
XU P.-X. ET AL.: "Regulation of Pax6 expression is conserved between mice and flies", DEVELOPMENT, vol. 126, no. 2, January 1999 (1999-01-01), pages 383 - 395, XP002105022 *

Also Published As

Publication number Publication date
WO1999031260A2 (fr) 1999-06-24
AU2053999A (en) 1999-07-05

Similar Documents

Publication Publication Date Title
Lee Extracellular regulation of myostatin: a molecular rheostat for muscle mass
WO2002000730A3 (fr) Molecules pd-l2 : nouveaux ligands de pd-1 et utilisations de ceux-ci
DE60035517D1 (de) Gl50 moleküle, sowie verwendungen derselben
ATE269402T1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
WO2001073060A3 (fr) 18221, nouveau phosphatase a specificite double et ses utilisations
WO2003042362A8 (fr) Pgc-1$g(b), un nouvel homologue du pgc-1 et leurs utilisations
ATE300619T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
CA2385444A1 (fr) Humanine, polypeptide inhibant la mort neuronnale
WO1999031260A3 (fr) Sequences regulatrices intervenant dans l'expression du gene specifique du pancreas
DE69832798D1 (de) Regulatorische sequenzen für die in-vivo-expression einer heterologen dns-sequenz in endothelzellen und ihre verwendungen.
WO2000077239A3 (fr) Nouveaux genes codant pour des proteines a des fins de diagnostic, de prevention, de therapie et autres
WO2003004613A3 (fr) Nouveaux isoformes de pgc-1 et applications de ceux-ci
WO2001076457A3 (fr) Compositions et methodes de diagnostic et traitement d'etats, troubles ou maladies impliques dans la mort cellulaire
DE60142356D1 (de) 18480 humane proteinkinasemoleküle und ihre verwendungen
WO2003018829A3 (fr) 6299, membre de la famille des carboxypeptidases a zinc humaines et utilisations associees
WO2004039307A3 (fr) Procedes et compositions destines au diagnostic et au traitement du cancer d'animaux de compagnie
WO2003020913A3 (fr) Acides nucleiques et proteines des genes du recepteur odorant des anopheles gambiae et utilisations correspondantes
WO2001000638A3 (fr) Nouveaux genes codant des proteines pouvant etre utilisees dans des domaines diagnostiques, preventifs, therapeutiques ou autres
WO2001066765A3 (fr) 26583, nouvelle serine/threonine phosphatase et utilisations correspondantes
WO2003020912A3 (fr) Nouvelle proteine cark et molecules d'acides nucleiques et leurs utilisation
WO2001066763A3 (fr) 23436, nouveau membre de la famille des proteases d'ubiquitine humaine et utilisations de celui-ci
WO2001064911A3 (fr) 18232, nouvelle phosphatase possedant une double specificite et ses utilisations
WO2002016588A3 (fr) A 15985, nouveau membre humain de la famille des proteines kinases serines/threonines, et ses utilisations
WO2001073050A3 (fr) 3714, 16742, 23546, et 13887 nouvelles molecules de proteine kinase et leurs utilisations
WO2001081588A3 (fr) 2246, molecules de proteine kinase et leurs utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase